Blood clots and the AstraZeneca COVID-19 vaccine – the EMA weighs in

astrazeneca COVID-19 vaccine blood clots

I have previously written about whether thrombosis (formation of blood clots) is linked to the AstraZeneca COVID-19 vaccine – my conclusions were that they probably weren’t. However, governments and the European Medicines Agency (EMA) are starting to make very concerned about an issue with this vaccine.

Recently, the government of Quebec recently decided that the AstraZeneca vaccine will only be used on individuals 55 years and older. Of course, this caused some parts of the anti-vaccine world to froth at the mouth claiming the vaccine isn’t safe.

Then, on 6 April 2021, the European Medicines Agency (EMA) is reporting a plausible link between the AstraZeneca vaccine and thrombotic events. I will discuss this in detail below.

I think that many of the adverse events that are claimed to be associated with any of the COVID-19 vaccines involve the post hoc ergo propter hoc fallacy, which states that because one event precedes another event, they must be linked. It is entirely possible that thrombosis occurs after vaccinations because of random chance rather than actual correlation (let alone causation). However, thrombosis that is temporally associated with the AstraZeneca vaccine may be troubling.

Because the AstraZeneca COVID-19 vaccine is one of the four main vaccines (along with those from Pfizer, Moderna, and JNJ) to be given in the USA, Canada, the EU, Australia, and New Zealand, I want to make sure that the potential of a causal link to blood clots are given a thorough analysis.

Continue reading “Blood clots and the AstraZeneca COVID-19 vaccine – the EMA weighs in”